ALSN
Allison Transmission Holdings, Inc.
ALSN has a slight edge over LCID overall, supported by lower modeled downside.
LCID
Lucid Group, Inc.
LCID offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
ALSN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Under pressure |
ALSN's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ALSN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $57.63 | -54% |
| Fair | 10x | $71.00 | -43% |
| Forward | 12x | $126 | — |
| Expensive | 15x | $102 | -19% |
| Current | 18x | $126 | — |
Historical ranges are pointers, not guarantees.
ALSN's PE is in its expensive range at 18x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its fair range.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
ALSN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ALSN, with profitability holding steady. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ALSN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.79 | +55% |
| Q3 2026 | $6.96 | -15% |
| Q2 2026 | $6.29 | -29% |
| Q1 2026 | $6.43 | -26% |
| Q4 2025 | $7.33 | -12% |
| Q3 2025 | $8.16 | -0.1% |
| Q2 2025 | $8.80 | +15% |
| Q1 2025 | $8.64 | +16% |
| Q4 2024 | $8.31 | +12% |
ALSN has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
ALSN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +121% |
| Q2 2026 | $1.6B | +92% |
| Q1 2026 | $1.4B | +84% |
| Q4 2025 | $737M | -7.4% |
| Q3 2025 | $693M | -16% |
| Q2 2025 | $814M | -0.2% |
| Q1 2025 | $766M | -2.9% |
| Q4 2024 | $796M | +2.7% |
ALSN's revenue has picked up after two years of holding roughly level: $1.5B last quarter, up 121% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -9.6 points |
| Q2 2026 | 19% | -13 points |
| Q1 2026 | 14% | -19 points |
| Q4 2025 | 23% | -6.3 points |
| Q3 2025 | 29% | -2.1 points |
| Q2 2025 | 31% | -0.8 points |
| Q1 2025 | 33% | +2.8 points |
| Q4 2024 | 30% | +0.5 points |
ALSN has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over ALSN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
ALSN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $278M | +51% |
| Q2 2026 | $281M | +84% |
| Q1 2026 | $103M | -34% |
| Q4 2025 | $169M | +24% |
| Q3 2025 | $184M | -12% |
| Q2 2025 | $153M | +2% |
| Q1 2025 | $155M | -4.3% |
| Q4 2024 | $136M | -27% |
ALSN has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
ALSN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -1M shares |
| 1 year | -1.2% | -1M shares |
| 3 years | -7.8% | -7M shares |
| 5 years | -22% | -23M shares |
| Available history | -33% | -40M shares |
ALSN has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $57M |
| Q2 2026 | $46M |
| Q1 2026 | $20M |
| Q4 2025 | $46M |
| Q3 2025 | $27M |
| Q2 2025 | $105M |
| Q1 2025 | $150M |
| Q4 2024 | $121M |
ALSN spent $169M buying back its own shares over the past year, down 58% from the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
ALSN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.8x | Moderate |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 4.0x | Elevated |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.5x | Healthy |
| Q4 2024 | 1.5x | Healthy |
ALSN's net debt is about 2.8 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALSN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 39.8 | Neutral |
ALSN's weekly RSI is 56 (neutral) and its Stochastic is 40 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ALSN PE vs Consumer Cyclical Sector
| Metric | ALSN | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 18x | 0.2% above |
| PE % | 95 | 47 | 48 pts above |
ALSN is trading at 18x earnings, in line with the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
ALSN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $113.8 | 10% above |
| 20 week MA | $118.6 | 6% above |
| 50 week MA | $116.1 | 8.2% above |
| 100 week MA | $105.7 | 19% above |
| 200 week MA | $87.0 | 44% above |
ALSN has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
ALSN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.7 | $43.3 | -11% |
| 2021 | $43.3 | $34.6 | -20% |
| 2022 | $34.6 | $42.3 | +22% |
| 2023 | $42.3 | $58.2 | +38% |
| 2024 | $58.2 | $108.7 | +87% |
| 2025 | $108.7 | $100.9 | -7.2% |
| 2026 YTD | $100.9 | $125.7 | +24% |
ALSN has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.